Skip to content
MARKETS / NASDAQ / SNTI
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Senti Biosciences Holdings, Inc. SNTI

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$22,000
$-61.4M
$-43.6M
In brief

What this company does

We are applying our gene circuit technologies to develop a pipeline of medicines that use chimeric antigen receptor (“CAR”) white blood cells with the goal of addressing major challenges and providing potentially lifesaving treatments for people living with cancer. Our lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in several oncology indications with high unmet need. Our lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase 1 clinical trial in the United States and Australia for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia (AML). On June 18, 2025, Senti Biosciences announced that the FDA has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia.

Written from the business description in Senti Biosciences Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.

Growth
USD 22,000.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -61.4
-25.0M-50.0M20212022202320242025
Compound annual growth
−81.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−279264 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -312631.8% · Net -279263.6%
-100000%-200000%-300000%20212022202320242025
ROE
FY2025 · ROE -393.4%
-200%-400%-600%20212022202320242025

Each USD of equity lost 393 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -43.6
-40M20212022202320242025

Total assetsUSD 51.2M
EquityUSD 5.6M
CashUSD 16.4M
Current ratio1.67×

Equity funds 11% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.0
Income tax $B0.00.0···
Net income $B−0.1−0.1−0.1−0.1−0.1
Free cash flow $B−0.0−0.0−0.1−0.1−0.0
EPS, diluted $−2.73−12.03−16.01−2.23−19.00
Dividend / sh $·····
Payout %·····
ROE %−393.4−114.1−73.2−736.6·
Shares out B0.030.000.000.040.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 20 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 56 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image